01696 SISRAM MED
- 4.260
- -0.050-1.16%
SISRAM MED News
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
The market is picking up, and listed companies are pouring in medical and aesthetic institutions. Who will win the next “C-rank material”?
Catalyzed by various factors, the medical and aesthetic market recovered to a certain extent in the first quarter, while the performance of listed companies, whether midstream medical and aesthetic institutions or upstream producers, has steadily improved since this year.
復銳醫療科技：2023年度報告
Fu Rui Medical Technology (01696) Innovative Hyaluronic Acid Product Profhilo Launched in Hainan
Profhilo is an innovative hyaluronic acid that corrects/fills natural and induced skin depressions to help ease the physiological process of skin aging, including reducing skin hydration, adjusting dermal elastic fibers and collagen, and improving skin filling defects and dull skin tone.
Express News | General Administration of Market Regulation: Maintain a high-pressure crackdown on illegal acts of medical and aesthetic advertising and strictly regulate the publication of medical and aesthetic advertisements
FuRui Medical Technology (01696.HK): 2023 results are under pressure, and we expect China to strengthen the registration and filling business
The 2023 results fell short of our expectations. The company announced 2023 results: revenue of US$359 million, +1.4% YoY; adjusted net profit of US$37.48 million, or -22.9% YoY. Due to macroeconomic factors in many regions
FuRui Medical Technology (01696.HK): Short-term performance disrupts during the transition period, concerns the injection sector is ready to go
Event: FuRui MedTech discloses 2023 results: 2023: Company revenue of $359 million (+1.4%) and net profit of $33 million (-17.9%) despite global challenges in 2023
FuRui Medical Technology (01696.HK): Short-term performance under multiple factors, pressure-pressurized injection lines are about to be approved domestically
Event: The company released its 2023 annual report. In 2023, we achieved revenue of US$359 million, up 1.4% year over year; realized adjusted net profit of US$38 million, down 22.9% year over year. Profit level: Increased gross margin
Sisram Medical's Profit Down in Fiscal 2023
Sisram Medical (HKG:1696) recorded a decline in attributable profit for the year ended Dec. 31, 2023, to $31.5 million from $40.2 million during the year-ago period, a Wednesday filing on the Hong Kon
Featured announcements | Tencent's Q4 revenue increased 7% year over year to 155.196 billion yuan; Kuaishou Q4 revenue increased 15.1% year over year to 32.561 billion yuan
Jinshan Software: Achieved net profit of 484 million yuan in 2023, with a proposed final interest of HK$0.14 per share; China Coal Energy: Profit attributable to shareholders increased by 2.3% to $20.084 billion in 2023, with a final interest rate of $442.
Press Release: Sisram Medical Announces 2023 Annual Results
Sisram Medical Announces 2023 Annual Results PR Newswire HONG KONG, March 20, 2024 Revenues of US$359.3M, with the direct sales portion reaching a record high HONG KONG, March 20, 2024 /PRNewswire
FuRui Medical Technology (01696) will pay a final dividend of HK$0.158 per share
FuRui Medical Technology (01696) announced that it will distribute final shares for the year ended December 31, 2023...
FuRui Medical Technology (01696.HK) annual profit decreased by 17.9% to US$32.9 million
Gelonghui March 20 | FuRui Medical Technology (01696.HK) announced that for the year ended December 31, 2023, the company's revenue was 359.3 million US dollars, an increase of 1.4% over last year's revenue. Gross margin increased from 57.0% in the same period in 2022 to 61.1% in the reporting period. Net cash flow from operating activities for the year was $43.9 million, up 99.4% from last year's net cash flow from operating activities. Profit for the year decreased by 17.9% to $32.9 million from $40.1 million in the same period in 2022. The board of directors decided to pay a final dividend
SISRAM MED: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Sisram Medical to Report FY2023 Financial Results on March 20 and Hold a Conference Call on March 21
Sisram FY2023 earnings conference call to be held on March 21, at 8:00 a.m. Eastern Time HONG KONG, March 14, 2024 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with
FuRui Medical Technology (01696.HK) plans to hold a board meeting on March 20 to approve the annual results
Gelonghui, March 8, 丨 Fu Rui Medical Technology (01696.HK) issued an announcement. The board of directors announced that the company's board of directors meeting will be held on March 20, 2024 (Wednesday) to consider and approve the Group's annual results for the year ended 31 December 2023, as well as the proposed final dividend (if any), and to deal with other matters.
SISRAM MED: DATE OF BOARD MEETING
Together in Barcelona, FuRui Medical Technology successfully held the 6th Alma Academy
Hong Kong, March 7, 2024 /PRNewswire/ -- March 7, 2024, FuRui Medical Technology Co., Ltd. (“Sisram”; “Company” or “FuRui Medical Technology” for short; stock code: 1696.HK; together with its subsidiaries, the “Group”) today announced that its subsidiary Alma successfully hosted the 6th Alma Academy offline event. The event was held in Barcelona from March 1 to 4, and hosted nearly 400 doctors from 37 countries around the world. FuRui Medical Technology is a global beauty and health group, which is unique
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
Express News | Fangzheng Securities: The cosmetics, medical and aesthetic industries are expected to usher in strong breakthroughs
Analysis
Price Target
No Data
